By mapping how specific microbial metabolites influence AKT and ERK activation states, new microbiota-targeted or combinatorial therapies could be designed to selectively suppress tumor-promoting pathways while enhancing antitumor immunity (50). This evidence concerns the gene AKT1 and neoplasm.